Emtricitabine/tenofovir/efavirenz (Atripla)

A combination of Emtricitabine a Nucleoside reverse transcriptase inhibitor, Tenofovir disoproxil fumarate a Nucleotide analogue reverse transcriptase inhibitor, and Efavirenz a Non-nucleoside a reverse transcriptase inhibitor.

A fixed-dose combination drug for the treatment of HIV infection.

By combining the three drugs into a single, once-daily pill reduces pill burden and simplifies dosing schedules, and therefore has the potential to increase adherence to antiretroviral therapy.

A fixed dose combination of 600 mg efavirenz, 300 mg tenofovir, and 200 mg emtricitabine.

Taken once daily on an empty stomach, with dosing at bedtime being recommended to improve tolerability of nervous system symptoms.

Not recommended for patients under 18 years of age.

Common side effects:tiredness, dizziness, gastrointestinal distress, and skin discoloration.

More severe side effects are hallucinations, sleeplessness and depression may occur.

Medications that should not be taken with this drug inlude: astemizole, bepridil), midazolam, (pimozide, triszolam), or ergot derivatives.

St. John’s wort is known to reduce the effectiveness, resulting in increased viral load and possible resistance.

Drugs that are contraindicated are: voriconazole, ergot derivative drugs, benzodiazepines midazolam and triazolam, calcium channel blocker bepridil, pimozide and St. John’s wort.

Breastfeeding is also contraindicated.

Leave a Reply

Your email address will not be published. Required fields are marked *